Platform of Pediatric Onco-Hematology research (CANSEARCH Laboratory), Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Bâtiment La Tulipe, Avenue de la Roseraie 64, 1205 Geneva, Switzerland.
Department of Women-Children-Adolescents, Division of General Pediatrics, Pediatric Onco-Hematology Unit, Geneva University Hospitals (HUG), Avenue de la Roseraie 64, 1205 Geneva, Switzerland.
Int J Mol Sci. 2019 Aug 9;20(16):3889. doi: 10.3390/ijms20163889.
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for several malignant and non-malignant diseases at the cost of serious treatment-related toxicities (TRTs). Recent research on extending the benefits of HSCT to more patients and indications has focused on limiting TRTs and improving immunological effects following proper mobilization and engraftment. Increasing numbers of studies report associations between HSCT outcomes and the expression or the manipulation of G protein-coupled receptors (GPCRs). This large family of cell surface receptors is involved in various human diseases. With ever-better knowledge of their crystal structures and signaling dynamics, GPCRs are already the targets for one third of the current therapeutic arsenal. The present paper assesses the current status of animal and human research on GPCRs in the context of selected HSCT outcomes via a systematized survey and analysis of the literature.
造血干细胞移植（HSCT）仍然是治疗几种恶性和非恶性疾病的唯一方法，但代价是严重的治疗相关毒性（TRTs）。最近，为了将 HSCT 的益处扩展到更多的患者和适应症，研究的重点是限制 TRTs，并在适当的动员和植入后改善免疫效果。越来越多的研究报告了 HSCT 结果与 G 蛋白偶联受体（GPCR）的表达或操纵之间的关联。这个庞大的细胞表面受体家族参与了各种人类疾病。随着对其晶体结构和信号动力学的了解越来越好，GPCR 已经成为当前三分之一治疗武器库的靶点。本文通过对文献进行系统的调查和分析，评估了 GPCR 在选定 HSCT 结果方面的动物和人类研究的现状。
